

Policy Name	Clinical Policy – Specialty Spectacle Lenses
Policy Number	1330.00
Department	Clinical Strategy
Subcategory	Medical Management
Original Approval Date	06/20/2018
Current MPC/CCO Approval Date	04/09/2025
Current Effective Date	08/01/2025

Company Entities Supported (Select All that Apply) <input checked="" type="checkbox"/> Superior Vision Benefit Management <input checked="" type="checkbox"/> Superior Vision Services <input checked="" type="checkbox"/> Superior Vision of New Jersey, Inc. <input checked="" type="checkbox"/> Block Vision of Texas, Inc. d/b/a Superior Vision of Texas <input checked="" type="checkbox"/> Davis Vision (Collectively referred to as 'Versant Health' or 'the Company')

ACRONYMS and DEFINITIONS	
D Diopter	The measurement unit for focusing power and refractive error
High Index	A lens fabrication that is lighter weight and has an increased impact resistance than standard lenses
Polycarbonate	A lens material with greater impact resistance than standard lenses
Trivex	A lens material with greater impact resistance than standard lenses
UV	Ultraviolet

PURPOSE

To provide the medical necessity criteria to support the indication(s) for specialty lenses. Applicable procedure codes are also defined.

POLICY

A. BACKGROUND

The industry standard for spectacle lenses is based on what is reasonable and recommended in clinical practice based on a variety of reasons including aesthetics, frame selection, and inherent properties of the lenses. In laymen's terms, thickness of lens edge compared to frame, lens qualities that make eyes appear larger or smaller, rimless plastic or metal frames, UV protection, and scratch resistance.

Medical necessity goes beyond lifestyle choices and addresses functional vision impairment. Factors contributing to medical necessity criteria are weight of the lens, optics, prescription strength, aberrations, optical quality, and induced prismatic effect.

High index lens materials often permit fabrication of thinner, lighter lenses that are more comfortable for the wearer and may provide added safety due to greater impact resistance.

Spectacle lenses are made from a variety of materials. The optimal choice for the patient depends on several factors: lens weight, thickness, resistance to scratches, shatter-resistance, and ultraviolet (UV) protection. Many other considerations need to be factored into lens selection related to the purpose of the eyeglasses, the activities of the wearer, and cost. Lens thickness is inversely proportional to refractive index. So, for the same prescription (Rx), a higher refractive index yields a thinner lens. Thinner lenses generally weigh less than thicker ones and are more comfortable to wear. The index of refraction of different lens materials are CR-39 plastic (1.50), crown glass (1.52), Trivex (1.53), polycarbonate (1.59), and high index plastics (1.60-1.74).

The American National Standard Institute's ANSI Z87 Committee has established impact resistance standards as well as minimum lens thickness. Lenses made from Trivex or polycarbonate have significantly more impact-resistance than other lens materials for added safety. A broken or shattered lens poses a severe safety hazard to the eye.

B. Medically Necessary

1. **Polycarbonate** lenses may be medically necessary for any of the following:
 - a. Patients with high ametropia (myopia greater than or equal to -6.00 or hyperopia greater than or equal to $+4.00$) diopters in any meridian¹
 - b. Patients under age 18
 - c. Patients who are monocular with functional vision in only one eye
 - d. As required for reasons of disability, or vocational, occupational, or recreational tasks
2. **High Index lenses**² may be considered medically necessary for \geq ± 8.00 diopters of refractive error in any meridian
3. **Transition/tint/photochromatic/ultraviolet blocking lenses** may be considered medically necessary for any of the following diagnoses:
 - a. Aniridia
 - b. Coloboma
 - c. Albinism
 - d. Ocular Albinism
 - e. Iridodialysis
 - f. Pigmentary retinal dystrophy³

¹ Borish Clinical Refraction, pgs. 869-877, 1166

² Borish Clinical Refraction, pgs. 869-877.

³ Otsuka, 2020.

g. Aphakia⁴

4. **FL 41 Filters** may be medically necessary for a diagnoses of blepharospasm⁵ and light induced migraine.⁶

C. Not Medically Necessary

Blue blocking lenses may not be medically necessary due to insufficient evidence in peer reviewed literature to support improved health outcomes⁷

Ultraviolet blocking lenses and tinted lenses are considered lifestyle or cosmetic in nature and may not be considered medically necessary except for conditions stated in section B.

D. Documentation

Medical necessity must be supported by adequate and complete documentation in the patient’s medical record that describes the medical rationale for specialty spectacle lenses, consistent with the medical necessity criteria enumerated above. The medical record must be available upon request to initiate or sustain previous payments. For any retrospective review, a full operative report and/or the clinical care plan is needed.

Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, date(s) of service). Services provided/ordered must be authenticated by the physician, in a handwritten or electronic signature. Stamped signatures are not acceptable.

E. Procedural Detail

HCPCS Codes	
S0580	Polycarbonate lens (list this code in addition to the basic code for the lens)
V2744	Tint, photochromatic, per lens
V2745	Addition to lens; tint, any color, solid, gradient, or equal, excludes photochromatic, any lens material, per lens
V2755	U-V lens, per lens
V2782	Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens (list this code in addition to the basic code for the lens)
V2783	Lens, index greater than or equal to 1.66 plastic or greater than or equal to 1.80 glass, excludes polycarbonate, per lens (list this code in addition to the basic code for the lens)

⁴ Liou, 2015.

⁵ Blackburn, 2009.

⁶ Reyes, 2024.

⁷ Singh, 2021.

V2784	Lens, polycarbonate or equal, any index, per lens (list this code in addition to the basic code for the lens)
Required Modifiers	
RT	right side
LT	left side

DISCLAIMER and COPYRIGHTS

This clinical policy is provided for information purposes only and does not constitute medical advice. Versant Health, Inc., and its affiliates (the “Company”) do not provide health care services and cannot guarantee any results or outcomes. Treating doctors are solely responsible for determining what services or treatments to provide to their patients. Patients (members) should always consult their doctor before making any decisions about medical care.

Subject to applicable law, compliance with this clinical policy is not a guarantee of coverage or payment. Coverage is based on the terms of an individual’s particular benefit plan document, which may not cover the service(s) or procedure(s) addressed in this clinical policy. The terms of the individual’s specific benefit plan are always determinative.

Every effort has been made to ensure that the information in this clinical policy is accurate and complete, however the Company does not guarantee that there are no errors in this policy or that the display of this file on a website is without error. The Company and its employees are not liable for any errors, omissions, or other inaccuracies in the information, product, or processes disclosed herein.

Neither the company nor the employees represent that the use of such information, products, or processes will not infringe on privately owned rights. In no event shall the Company be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information, product, or process.

COMPANY’S COPYRIGHT STATEMENT Except for any copyrights described below, this clinical policy is confidential and proprietary, and no part of this clinical policy may be copied, distributed or used without Versant Health, or its applicable affiliates, express prior written approval.

AMA COPYRIGHT STATEMENT CPT© is the 2002-2025 copyright of the American Medical Association. All Rights Reserved. CPT™ is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

RELATED POLICIES AND PROCEDURES	
1309	Medically Necessary Contact Lenses

DOCUMENT HISTORY		
<i>Approval Date</i>	<i>Revisions</i>	<i>Effective Date</i>
06/20/2018	Initial Policy	06/20/2018
07/25/2019	Minor revisions	08/01/2019
06/03/2020	Add specific criteria for transitional lenses, light filter/tints, and polycarbonate coatings; policy renamed.	09/01/2020
04/07/2021	Restated the metric for high ametropia for poly carbonate lenses to any meridian from “spherical equivalent. Added 5 CPT codes for lens tints and chromatic coatings.	09/01/2021
04/06/2022	Annual review; no criteria changes	07/01/2022
04/12/2023	Annual review; no criteria changes. Add 4 add on codes to configuration. Codes are not new to policy.	n/a not effected
04/24/2023	2 nd review for Q2 2023: Change parameters of high ametropia for polycarbonate lenses from >6 to ≥ -6.00 or ≥ +4.00 in any meridian. Add ≥ sign to current measure (+/- 8.00 diopters) for high index lenses.	08/01/2023
04/03/2024	For polycarbonate lenses, removed visual acuity requirements for monocular patients; clarified blue blocking lenses are not medically necessary.	n/a not effected
04/16/2024	Adjusted list formatting to clarify that polycarbonate lenses may be medically necessary for standalone reasons of disability, vocational or occupational risks, or recreational tasks.	07/01/2024
04/09/2025	For photochromatic lenses add indications of pigmentary retinal dystrophy and aphakia. For FL-41 filters add indication of light induced migraines.	08/01/2025

REFERENCES AND SOURCES

1. Atchison DA, Smith G, Johnston AW. Prismatic effects of spherical ophthalmic lenses. *Am J Optom Physiol Opt.* 1980 Nov;57(11):779-90. doi: 10.1097/00006324-198011000-00001. PMID: 7446685.
2. Blackburn MK, Lamb RD, Digre KB, et.al. FL-41 tint improves blink frequency, light sensitivity, and functional limitations in patients with benign essential blepharospasm. *Ophthalmology.* 2009 May;116(5):997-1001. doi: 10.1016/j.ophtha.2008.12.031. PMID: 19410958; PMCID: PMC2701948. Bressler NM. Reducing the Progression of Myopia. *JAMA (Journal of the American Medical Association).* 2020 Aug 11;324(6):558-559. doi: 10.1001/jama.2020.10953. PMID: 32780128.
3. Borish, IM, and William JB. Borish's clinical refraction. Clinical textbook, WB Saunders, 1998.
4. Bryant, Robert J.[†]. Lens retention performance of safety frames*. *Optometry and Vision Science* 46(4): p 265-269, April 1969. Clinical textbook.
5. Doroslovački P, Guyton DL. Photographic simulation of off axis blurring due to chromatic aberration in spectacle lenses. *J AAPOS.* 2015 Feb;19(1):91-3. doi: 10.1016/j.jaapos.2014.09.010. PMID: 25727601.
6. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. *Cochrane Database Syst Rev.* 2012;(9):CD007146. Published Sep 2012.
7. Hoggan RN, Subhash A, Blair S, et al. Thin-film optical notch filter spectacle coatings for the treatment of migraine and photophobia. *J Clin Neurosci.* 2016;28:71-76. doi:10.1016/j.jocn.2015.09.024.
8. Hoskin AK, Philip S, Dain SJ, et.al. Spectacle-related eye injuries, spectacle-impact performance, and eye protection. *Clin Exp Optom.* 2015 May;98(3):203-9. doi: 10.1111/cxo.12283. PMID: 25963111.
9. Liou JC, Teng MC, Tsai YS, Lin EC, Chen BY. UV-blocking spectacle lens protects against UV-induced decline of visual performance. *Mol Vis.* 2015;21:846-856. Published 2015 Aug 6.
10. Mohammed Jalie (2020) Modern spectacle lens design, *Clinical and Experimental Optometry*, 103:1, 3-10, DOI: 10.1111/cxo.12930
11. Jhetam S, Mashige KP. Effects of spectacles and telescopes on visual function in students with oculocutaneous albinism. *Afr Health Sci.* 2020 Jun;20(2):758-767. doi: 10.4314/has.v20i2.28. PMID: 33163041; PMCID: PMC7609099.
12. Lambert SR, DuBois L, Cotsonis G, et al. Infant Aphakia Treatment Study Group. Spectacle Adherence Among Four-Year-Old Children in the Infant Aphakia Treatment Study. *Am J Ophthalmol.* 2019 Apr; 200:26-33. doi: 10.1016/j.ajo.2018.12.017. Epub 2019 Jan 8. PMID: 30633891; PMCID: PMC6445735.
13. Otsuka Y, Oishi A, Miyata M, et al. Wavelength of light and photophobia in inherited retinal dystrophy. *Sci Rep.* 2020;10(1):14798. Published 2020 Sep 9. doi:10.1038/s41598-020-71707-2.
14. Pillay R, Hansraj R, Rampersad N. Historical Development, Applications and Advances in Materials Used in Spectacle Lenses and Contact Lenses. *Clin Optom (Auckl).* 2020 Sep 29; 12:157-167. doi: 10.2147/OPTO.S257081. PMID: 33061731; PMCID: PMC7532918.

15. Reyes N, Huang JJ, Choudhury A, et al. FL-41 Tint Reduces Activation of Neural Pathways of Photophobia in Patients with Chronic Ocular Pain. *I am J Ophthalmol.* 2024;259:172-184. doi:10.1016/j.ajo.2023.12.004.
16. Singh S, Downie LE, Anderson AJ. Do Blue-blocking Lenses Reduce Eye Strain from Extended Screen Time? A Double-Masked Randomized Controlled Trial. *Am J Ophthalmol.* 2021 Jun; 226:243-251. doi: 10.1016/j.ajo.2021.02.010. Epub 2021 Feb 12. PMID: 33587901.
17. Singh S, Keller PR, Busija L, et.al. Blue-light filtering spectacle lenses for visual performance, sleep, and macular health in adults. *Cochrane Database Syst Rev.* 2023 Aug 18;8(8):CD013244. doi: 10.1002/14651858.CD013244.pub2. PMID: 37593770; PMCID: PMC10436683.
18. Su B, Cho P, Vincent SJ, et al. Novel Lenslet-ARray-Integrated Spectacle Lenses for Myopia Control: A 1-Year Randomized, Double-Masked, Controlled Trial. *Ophthalmology.* 2024;131(12):1389-1397. doi: 10.1016/j.optha.2024.07.002.
19. Ţone S, Niagu IA, Bogdănici ŞT, et.al. Update in pediatric myopia treatment strategies. *Rom J Ophthalmol.* 2020 Jul-Sep;64(3):233-238. PMID: 33367156; PMCID: PMC7739548.
20. Van de Bruaene C, Flamant T, Rogiers P. A breathtaking spectacle. *Eur J Intern Med.* 2020 Mar; 73:92-93. doi: 10.1016/je.jim.2019.12.027. Epub 2020 Jan 3. PMID: 31902563.
21. Vinger, Paul F., and Thomas A. Woods. "Prescription Safety Eyewear Impact Studies of Lens and Frame Failure." Paper presented at the ASSE Professional Development Conference and Exhibition, Baltimore, Maryland, June 1999.
22. Vinger, PF, Parver, L, et al. Shatter Resistance of Spectacle Lenses, *JAMA.* 1997; 277(2):142-144.
23. Wang J, Feng L, Wang Y. et.al. Binocular benefits of optical treatment in anisometropic amblyopia. *J Vis.* 2018; 18(4):6.

SOURCES

1. American Academy of Ophthalmology. Refractive Errors Preferred Practice Pattern. 2022. [https://www.aaojournal.org/article/S0161-6420\(22\)00867-3/pdf](https://www.aaojournal.org/article/S0161-6420(22)00867-3/pdf). Accessed 2/2025.
2. Eyeglass lenses must comply with impact resistance standards; American National Standard Institute, ANSI Z80.1-2010. [https://webstore.ansi.org/standards/vc%20\(asc%20z80\)/ansiz802010?_gl=1*q3ht3l*_gcl_au*NjcwMDQwNzI2LjE3MDY5MTE0NDM](https://webstore.ansi.org/standards/vc%20(asc%20z80)/ansiz802010?_gl=1*q3ht3l*_gcl_au*NjcwMDQwNzI2LjE3MDY5MTE0NDM). Accessed 2/2025.
3. U.S. Dept. Of Defense. Report: Polycarbonate Versus CR-39 Lenses: A Field Study. <https://apps.dtic.mil/sti/citations/ADA091656>. Accessed 2/2025.